Recombinant factor VIIa (NovoSeven) in intracerebral haemorrhage (ICH) - horizon scanning review
NHSC
Record ID 32004000881
English
Authors' objectives:
To summarise the currently available evidence on recombinant factor VIIa (NovoSeven) in intracerebral haemorrhage (ICH).
Authors' recommendations:
Recombinant factor VIIa (rFVIIa, NovoSeven) is available in the UK for the treatment of spontaneous and surgical bleeding in patients with haemophilia and inhibitors to factors VIII and IX, people with Glanzmann's thrombasthenia refractory to platelet transfusions, and those with factor VII deficiency. Results from a randomised phase II trial of rFVIIa in acute intracerebral haemorrhage (ICH) found a significant reduction in ongoing bleeding, with a trend towards reduced mortality.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Factor VIIa
- Recombinant Proteins
- Blood Coagulation Disorders
- Cerebral Hemorrhage
- Factor VII Deficiency
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.